Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Contribution of Next Generation Flow (NGF) Cytometry in Primary Immune Thrombocytopenia (ITP): Utility for the Differential Diagnosis with Myelodysplastic Syndromes

Tomas Jose Gonzalez-Lopez, Sergio Matarraz, Isabel Caparros, María Fernanda López Fernández, Maria Eva Mingot, Ana Jiménez, Fernando Fernandez-Fuertes, José Ignacio Sánchez-Gallego, Pilar Leoz, Beatriz Cuevas, Maria Victoria Cuevas, Cristina Martin Marin, Juan Olazabal Herrero, Pilar de Vicente, Alberto Orfao

Blood (2021) 138 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2021-152182

Published: 2021

Journal Articles

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Blood (2021) 138 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2021-146021

Published: 2021

Journal Articles

Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study

Adrian C. Newland, Jean-Francois Viallard, María Fernanda López Fernández, Melissa Jeanne Eisen, Hossam A Saad, Jane Hippenmeyer, Bertrand Godeau

Blood (2021) 138 (Supplement 1): 3157.

https://doi.org/10.1182/blood-2021-150257

Published: 2021

Journal Articles

Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Blood (2019) 134 (Supplement_1): 1088.

https://doi.org/10.1182/blood-2019-125557

Published: 2019

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Blood (2019) 134 (Supplement_1): 2370.

https://doi.org/10.1182/blood-2019-125580

Published: 2019

Journal Articles

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Blood (2018) 132 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2018-99-112447

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Brigitte Brand, Ralph A. Gruppo, MD, Tung T. Wynn, Laimonas Griskevicius, Maria Fernanda Lopez Fernandez, Thomas Dvorak, Lisa Patrone, Brigitt E. Abbuehl

Blood (2015) 126 (23): 2299.

https://doi.org/10.1182/blood.V126.23.2299.2299

Published: 2015

Journal Articles

Case-Control Pilot Study of the Immune Modulating Effect of FEIBA ® on Patients with Haemophilia a and Inhibitors

Ihosvany Fernandez Bello, PhD, María Teresa Álvarez Román, PhD, Victor Jiménez Yuste, PhD, Monica Martín Salces, Gemma Iruin, PhD, Santiago Bonanad, PhD, María Fernanda López Fernández, PhD, Carmen Altisent, PhD, Faustino García Candel, PhD, María Isabel Rivas Pollmar, Miguel Canales, PhD, Nora Butta, PhD

Blood (2015) 126 (23): 4688.

https://doi.org/10.1182/blood.V126.23.4688.4688

Published: 2015

Journal Articles

A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim

Adrian Newland, Bertrand Godeau, Victor Priego, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Amelia Orejudos, Angela Lopez

Blood (2014) 124 (21): 2775.

https://doi.org/10.1182/blood.V124.21.2775.2775

Published: 2014

Journal Articles

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Roberto Stasi, MD, PhD, Adrian Newland, Bertrand Godeau, Victor Priego, MD, Jean-Francois Viallard, Maria Fernanda Lopez Fernandez, Catherine Jia, Angela Lopez

Blood (2013) 122 (21): 1074.

https://doi.org/10.1182/blood.V122.21.1074.1074

Published: 2013

Journal Articles

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Ann Janssens, MD, Michael D. Tarantino, MD, Robert Bird, MD, Maria Gabriella Mazzucconi, MD, Ralph Vincent V. Boccia, MD, Maria Fernanda Lopez-Fernandez, MD, Tomas Kozak, MD, Michael Steurer, MD, Peter A.W. Te Boekhorst, MD, PhD, Kerry Dillingham, MSc, Richard Lizambri, MD

Blood (2011) 118 (21): 3279.

https://doi.org/10.1182/blood.V118.21.3279.3279

Published: 2011

Journal Articles

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Blood (2011) 118 (21): 1262.

https://doi.org/10.1182/blood.V118.21.1262.1262

Published: 2011

NARROW

Contribution of Next Generation Flow (NGF) Cytometry in Primary Immune Thrombocytopenia (ITP): Utility for the Differential Diagnosis with Myelodysplastic Syndromes

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study

Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up

Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Perioperative Efficacy of an Extended Half-Life, Pegylated, Full-Length, Recombinant Factor VIII (BAX 855) in Individual Procedures

Case-Control Pilot Study of the Immune Modulating Effect of FEIBA ® on Patients with Haemophilia a and Inhibitors

A Final Analysis of a Phase 2, Single-Arm Study of Platelet (Plt) Responses and Remission Rates in Patients with Immune Thrombocytopenia (ITP) Receiving Romiplostim

An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only